SBI Securities’s Silexion Therapeutics SLXN Stock Holding History

SBI Securities’s Portfolio SLXN Stock Details SLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$26	Sell	2 -104	-98%	-$1.82K	﹤0.01%	3717
2025 Q4	$2.04K	Hold	106	–	–	﹤0.01%	2371
2025 Q3	$3.6K	Sell	106 -3	-3%	-$249	﹤0.01%	2188
2025 Q2	$13.3K	Hold	109	–	–	﹤0.01%	1581
2025 Q1	$18.1K	Buy	+109	New	+$21.6K	﹤0.01%	1373

Other funds holding SLXN

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

SBI Securities's SLXN Position: Q1 2026 in Review

SBI Securities reduced its Silexion Therapeutics (SLXN) stake by 98% in Q1 2026, selling an estimated $1.82K and leaving 2 shares worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

SBI Securities first reported a position in SLXN in Q1 2025 and has held it in 5 quarters since. The position peaked at $18.1K in Q1 2025. 7 funds tracked by Wall St. Rank hold SLXN as of Q1 2026.

SBI Securities held 2 shares of Silexion Therapeutics worth $26 as of Q1 2026.
SBI Securities sold 104 Silexion Therapeutics shares in Q1 2026, an estimated $1.82K.
Silexion Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3717 holding.
SBI Securities first reported a position in Silexion Therapeutics in Q1 2025 and has held it in 5 quarters since.
SBI Securities's Silexion Therapeutics position peaked at $18.1K in Q1 2025.
7 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.